Chronic neutrophilic leukemia diagnostic study of choice

	Chronic neutrophilic leukemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Screening
Differentiating Chronic neutrophilic leukemia from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT scan
MRI
Echocardiography and Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Chronic neutrophilic leukemia diagnostic study of choice On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Chronic neutrophilic leukemia diagnostic study of choice All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Chronic neutrophilic leukemia diagnostic study of choice
CDC on Chronic neutrophilic leukemia diagnostic study of choice
Chronic neutrophilic leukemia diagnostic study of choice in the news
Blogs on Chronic neutrophilic leukemia diagnostic study of choice
Directions to Hospitals Treating Chronic neutrophilic leukemia
Risk calculators and risk factors for Chronic neutrophilic leukemia diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2].

Overview

World health organization (WHO) introduces criteria for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the laboratory finding of peripheral blood cells, bone marrow, cytogenic mutation, and differential diagnosis.

The diagnosis of CNL is based on the WHO criteria, which include:^[1]

World Health Organization (WHO) Criteria for CNL diagnosis
1. Peripheral blood White blood cells (WBC) ≥25 ×10⁹/L:	Segmented neutrophils plus band forms ≥80% of WBC Neutrophil precursors <10% of WBC Myeloblasts rarely observed Monocyte count <1 ×10⁹/L No dysgranulopoies.
2. Hypercellular bone marrow:	Neutrophil granulocytes increased in percentage and number Normal neutrophil maturation Myeloblasts <5% of nucleated cells
3. Not meeting WHO criteria for:	BCR-ABL1+ chronic myeloid leukemia, Polycythemia vera Essential thrombocythemia Primary myelofibrosis
4. No rearrangement of:	PDGFRA PDGFRB FGFR1 PCM1-JAK2
5.Presence of CSF3RT618I or other activating CSF3R mutation or In the absence of a CSFR3R mutation, persistent neutrophilia (at least 3 months), splenomegaly, and no identifiable cause of reactive neutrophilia including the absence of a plasma cell neoplasm or, if present, demonstration of clonality of myeloid cells by cytogenetic or molecular studies.

↑ Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.